Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

Launched by CHONGQING MEDICAL UNIVERSITY · Aug 2, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new blood test marker called the high sensitivity C-reactive protein to albumin ratio (hsCAR) to see if it can help doctors identify patients with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and to determine if these patients have liver fibrosis, which is a condition where the liver becomes scarred. The study is currently recruiting participants aged 65 to 74 who have been diagnosed with MAFLD. This condition is linked to factors like being overweight, having diabetes, or other metabolic issues.

To be eligible for this trial, participants need to have a confirmed diagnosis of MAFLD and meet certain health criteria, such as having a specific body weight or blood sugar levels. Participants will contribute data from their health records and may undergo tests to check their liver condition. It’s important to note that individuals under 18 or those with cancer are not eligible for this study. By participating, individuals may help researchers understand more about the relationship between hsCAR and liver health, which could lead to better ways to diagnose and treat liver-related issues in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Total participants from NHANES 2017-2020
• • Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.
• • 1. Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL).
• • 2. Overweight or obesity: defined as BMI≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians
• 3. If presence of at least two metabolic risk abnormalities:
• • Waist circumference≥102/88 cm in Caucasian men and women (or≥90/80 cm in Asian men and women)
• • Blood pressure≥130/85 mmHg or specific drug treatment
• • Plasma triglycerides≥150 mg/dl (≥1.70 mmol/L) or specific drug treatment
• • Plasma HDL-cholesterol \<40 mg/dl (\<1.0 mmol/L) for men and \<50 mg/dl (\<1.3 mmol/L) for women or specific drug treatment
• • Prediabetes (i.e., fasting glucose levels 100 to 125 mg/dl \[5.6 to 6.9 mmol/L\], or 2-hour post-load glucose levels 140 to 199 mg/dl \[7.8 to 11.0 mmol\] or HbA1c 5.7% to 6.4% \[39 to 47 mmol/mol\])
• • Homeostasis model assessment of insulin resistance score≥2.5
• • Plasma high-sensitivity C-reactive protein level \>2 mg/L
• Exclusion Criteria:
• • Liver ultrasound data not available
• • participants without complete clinical data
• • participants under 18 years old
• • participants with cancer.